Beyond the FDA clearance for Decnupaz, AbbVie’s broader antibody-drug conjugate strategy keeps delivering. Coverage noted that the BPDCN approval leverages Decnupaz’s lineage from AbbVie’s 2023 ImmunoGen acquisition, underscoring how the transaction is translating into new regulatory milestones. From a pipeline-management perspective, the approval also highlights the company’s focus on CD-targeted payload delivery in hematologic cancers, where ADC mechanisms can differentiate from small molecules and standard chemotherapy. As more ADCs reach market, the company’s ability to expand clinical evidence and refine patient selection becomes a key driver of uptake. Analysts and clinicians are watching for further label expansion as AbbVie builds long-term commercial momentum from single-asset regulatory successes.